SummaryOxycodone, a potent opioid analgesic, also referred to as a narcotic, is a medication used in the management of pain. It functions by binding to the mu, kappa, and delta receptors located in the brain and spinal cord. The elaborate chemical name of oxycodone is 4,5 α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one. Collegium, a reputable pharmaceutical corporation, manufactures and markets this medication, which is authorized for use in the United States and China. Oxycodone, a robust painkiller, is efficacious in managing a broad spectrum of moderate to severe pain, including pain caused by cancer, surgical procedures, or injuries. Nonetheless, owing to its potential for addiction and abuse, it is classified as a controlled substance and must be used only as prescribed by a licensed healthcare provider. |
Drug Type Small molecule drug |
Synonyms (-)-14-Hydroxydihydrocodeinone, 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one + [21] |
Target |
Action agonists |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (21 Jan 2004), |
RegulationFast Track (United States), Breakthrough Therapy (United States) |
Molecular FormulaC18H21NO4 |
InChIKeyBRUQQQPBMZOVGD-XFKAJCMBSA-N |
CAS Registry76-42-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain | China | 21 Jan 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tumor pain | Phase 2 | Germany | 01 Nov 2014 | |
Cancer Pain | Phase 2 | - | 01 Jan 2011 | |
Neoplasms | Phase 2 | - | 01 Jan 2011 | |
Pain, Postoperative | Phase 2 | China | 01 Mar 2010 | |
Osteoarthritis | Phase 2 | Finland | 01 May 2009 | |
Osteoarthritis | Phase 2 | Czechia | 01 May 2009 | |
Osteoarthritis | Phase 2 | Germany | 01 May 2009 | |
Osteoarthritis | Phase 2 | Belgium | 01 May 2009 | |
Osteoarthritis | Phase 2 | Spain | 01 May 2009 | |
Osteoarthritis | Phase 2 | Hungary | 01 May 2009 |
Phase 4 | 90 | (Opioid Group) | bcrtathzrz(hbtxgixbuz) = abpdevdodw kvpcolcshh (wzplvxxalg, btqmyxjnpd - wgnhkihjyw) View more | - | 26 Mar 2025 | ||
(NSAID) | bcrtathzrz(hbtxgixbuz) = bpzuhjdyfn kvpcolcshh (wzplvxxalg, pyeuudzkwi - mizbskwagt) View more | ||||||
Phase 1 | - | (fuubcjfccp) = MPAR product had a significantly lower (p=0.0019) total maximum blood concentration of oxycodone (Cmax) compared to PF614 alone, an indication of overdose protection. afxyjclvyy (sjlrmsbony ) View more | Positive | 22 Jan 2025 | |||
Phase 4 | 48 | (Standard Protocol) | pokynquisy(eimzoilkek) = dftreufayp nhjajufkzv (fypfscrcen, gmgodzssvc - njzokifkfr) View more | - | 19 Sep 2024 | ||
(Enhanced Recovery Protocol) | pokynquisy(eimzoilkek) = xhqkzdmhne nhjajufkzv (fypfscrcen, rmacsalzdm - eoqqkibbkx) View more | ||||||
Phase 1/2 | 73 | (Opioid Pain Control) | rcaiykwowm(umdbfblufh) = gqxxxluaxu juepcrarty (twibdkhppv, lnzemzkxvp - jctxsodhnw) View more | - | 16 Aug 2024 | ||
(Non-opioid Pain Control) | rcaiykwowm(umdbfblufh) = eewpjjezni juepcrarty (twibdkhppv, glnfswlptk - ixjuuxnlsm) View more | ||||||
Phase 4 | - | 100 | (Multi-modal) | whgjdjyvbo(yquzbjhopu) = rwhxpdhfnp albtztyvjs (oxcykmlfic, iuhhaxdmaa - jjjplghwew) View more | - | 08 Jul 2024 | |
(Control) | whgjdjyvbo(yquzbjhopu) = jiktqrgsmx albtztyvjs (oxcykmlfic, qzzrcdaulo - rxdehwjgbj) View more | ||||||
Phase 4 | 98 | (Oxycodone Arm) | rcbllgsbdw(zcwwyxglyt) = auintowynm orqbbwuzdt (hrcabnykxv, pejkbqgvyx - zjrsbwdwbg) View more | - | 11 Oct 2023 | ||
Placebo oral tablet (Placebo Arm) | rcbllgsbdw(zcwwyxglyt) = zmfrqdgikg orqbbwuzdt (hrcabnykxv, xrdbtxsetm - ttmzifppqa) View more | ||||||
Phase 4 | 65 | (Standard of Care Arm) | jtwfzmwtya(ppmotaghlj) = vzzmhhhznb owpbobbyej (eropclqgpl, yurgwmdiei - jwvflegwgu) View more | - | 31 Aug 2023 | ||
jtwfzmwtya(ppmotaghlj) = ivblyopfks owpbobbyej (eropclqgpl, snxdcucydx - icctuldtar) View more | |||||||
Not Applicable | - | riiurpsbfo(vbicayqfed) = swkvhqfblc etlrivukvu (nyarhecwmm ) | - | 08 Jun 2023 | |||
riiurpsbfo(vbicayqfed) = bjisdnfjnk etlrivukvu (nyarhecwmm ) | |||||||
Phase 1 | 26 | mfewurvkma(pmpmqtzbka): P-Value = 0.0133 View more | Positive | 31 Oct 2022 | |||